Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIZE Global: Phase 3 Study of Sodium Zirconium Cyclosilicate in Hyperkalemia
jRCT2080223490Phase 3
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium zirconium cyclosilicate in hyperkalemia (3 arms), sponsored by AstraZeneca.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on jRCT2080223490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223490.